Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2015-10-31
2021-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitiligo Diagnosed Group
Clinically diagnosed with non-segmental vitiligo
Punch Biopsy at a Lesional Site
Punch Biopsy at a Non- Lesional site
Healthy Control Group
20 normally pigmented control subjects who are between the ages of 18 and 50
Punch Biopsy at a Non- Lesional site
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Punch Biopsy at a Lesional Site
Punch Biopsy at a Non- Lesional site
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have a clinical exam consistent with and diagnosis of non-segmental vitiligo
* Must be normally pigmented
* No clinical presentation of vitiligo
Exclusion Criteria
* No clinical diagnosis of vitiligo
* Use of systemic therapies, including but not limited to methotrexate, etretinate, or cyclosporine, calcineurin inhibitors and/ or vitamin D analogs within 4 weeks of enrollment
* Use of topical steroids or topical immunodilators at biopsy site within 4 weeks of enrollment
* History of keloids or hypertrophic scars
* Patients with pacemakers or defibrillators or heart valves
* Patients on Plavix, Warfarin or similar anticoagulation medicine
* Pregnant females
* Lactating women
* Allergies or sensitivity to lidocaine or epinephrine
* Outside of the specified age range
* Abnormally pigmented at potential biopsy sites (non-vitiligo)
* Clinical presentation of vitiligo
* Use of systemic therapies, including but not limited to methotrexate, etretinate, or cyclosporine, calcineuron inhibitors and/ or vitamin D analogs within 4 weeks of enrollment
* Use of topical steroids or topical immunodilators at biopsy site within 4 weeks of enrollment
* History of keloids or hypertrophic scars
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prashiela Manga, MD
Role: PRINCIPAL_INVESTIGATOR
New York University Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York University School of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-00445
Identifier Type: -
Identifier Source: org_study_id